The US pharmaceutical market is the largest in the world, projected to be worth nearly US$350bn by 2015, according to IMS Health, and growth among domestic companies looks set to continue. According to a new Pharma Insights report on the US market published as a joint venture by CPhI Worldwide and InformEx, just under half of the domestic companies questioned said they would be increasing their investment spending by at least 10% this year and a quarter by more than 15%.
A further sign of optimism is that 40% of companies said they would be increasing headcount this year. A further 50% had no plans to alter headcount – an indication of stability across the market – while just 8% of respondents are cutting headcount and consolidating. In addition, a quarter of companies asked are planning an international acquisition in the next 1–3 years, with a further 12.5% planning domestic acquisition.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.